ES2655190T3 - Prevención y tratamiento de la infección por Mycobacterium - Google Patents

Prevención y tratamiento de la infección por Mycobacterium Download PDF

Info

Publication number
ES2655190T3
ES2655190T3 ES12859440.5T ES12859440T ES2655190T3 ES 2655190 T3 ES2655190 T3 ES 2655190T3 ES 12859440 T ES12859440 T ES 12859440T ES 2655190 T3 ES2655190 T3 ES 2655190T3
Authority
ES
Spain
Prior art keywords
tuberculosis
cysdnc
dna
gene
sap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12859440.5T
Other languages
English (en)
Spanish (es)
Inventor
James Anthony TRICCAS
Rachel PINTO-NADANACHANDRAN
Warwick John BRITTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Inst Of Cancer Medicine And Cell Biology
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Original Assignee
Centenary Inst Of Cancer Medicine And Cell Biology
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centenary Inst Of Cancer Medicine And Cell Biology, Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney filed Critical Centenary Inst Of Cancer Medicine And Cell Biology
Application granted granted Critical
Publication of ES2655190T3 publication Critical patent/ES2655190T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07004—Sulfate adenylyltransferase (2.7.7.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12859440.5T 2011-12-22 2012-12-20 Prevención y tratamiento de la infección por Mycobacterium Active ES2655190T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579166P 2011-12-22 2011-12-22
US201161579166P 2011-12-22
PCT/AU2012/001569 WO2013091004A1 (en) 2011-12-22 2012-12-20 Prevention and treatment of mycobacterium infection

Publications (1)

Publication Number Publication Date
ES2655190T3 true ES2655190T3 (es) 2018-02-19

Family

ID=48667508

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12859440.5T Active ES2655190T3 (es) 2011-12-22 2012-12-20 Prevención y tratamiento de la infección por Mycobacterium

Country Status (7)

Country Link
US (2) US9610337B2 (enExample)
EP (1) EP2794885B1 (enExample)
CN (1) CN104271744B (enExample)
AU (1) AU2012357637B9 (enExample)
ES (1) ES2655190T3 (enExample)
IN (1) IN2014DN05865A (enExample)
WO (1) WO2013091004A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
EP3743103A4 (en) * 2018-01-26 2021-03-17 The Regents of The University of California INTRANASAL ADMINISTRATION OF CYCLIC DI-NUCLEOTIDE ADJUVED VACCINE FOR TUBERCULOSIS
CA3098015A1 (en) * 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria
WO2021243417A1 (en) * 2020-06-05 2021-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Immunogenic formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ309945A (en) * 1995-05-23 2001-04-27 Univ California Abundant extracellular products and their use as vaccines
WO2002004018A2 (en) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
WO2002086067A2 (en) 2001-04-20 2002-10-31 The Regents Of The University Of California Mycobacterial sulfation pathway proteins and methods of use thereof
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2355798A1 (en) * 2008-11-12 2011-08-17 Statens Serum Institut Modified cationic liposome adjuvans

Also Published As

Publication number Publication date
CN104271744A (zh) 2015-01-07
US9931391B2 (en) 2018-04-03
US9610337B2 (en) 2017-04-04
IN2014DN05865A (enExample) 2015-05-22
AU2012357637B9 (en) 2017-10-19
EP2794885B1 (en) 2017-10-04
EP2794885A1 (en) 2014-10-29
CN104271744B (zh) 2017-06-06
US20170173137A1 (en) 2017-06-22
EP2794885A4 (en) 2015-07-22
US20160022795A1 (en) 2016-01-28
WO2013091004A1 (en) 2013-06-27
AU2012357637B2 (en) 2017-09-21
AU2012357637A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
Tizard Vaccines for Veterinarians E-Book
Witcombe et al. Strategies for anti-coccidial prophylaxis
Huang et al. Safety and immunogenicity of an oral DNA vaccine encoding Sip of Streptococcus agalactiae from Nile tilapia Oreochromis niloticus delivered by live attenuated Salmonella typhimurium
La Ragione et al. Efficacy of a live attenuated Escherichia coli O78∶ K80 vaccine in chickens and turkeys
US20220125901A1 (en) Treatment of cancer using recall antigens delivered by attenuated bacteria
Conlan et al. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization
Lee et al. Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection
Stukova et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein
UA113496C2 (xx) Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter
BR112015019283B1 (pt) Composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora
Tabynov et al. Novel vector vaccine against Brucella abortus based on influenza A viruses expressing Brucella L7/L12 or Omp16 proteins: evaluation of protection in pregnant heifers
Liu et al. Immune responses and protection induced by Brucella suis S2 bacterial ghosts in mice
Venkatesan et al. Combination vaccines against diarrheal diseases
Niborski et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV
ES2824402T3 (es) Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas
Yang et al. Anti-caries vaccine based on clinical cold-adapted influenza vaccine: A promising alternative for scientific and public-health protection against dental caries
Martin et al. The combination of plasmid interleukin‐12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette–Guèrin) in protecting against systemic Mycobacterim avium infection
Bugybayeva et al. Development of human vectored brucellosis vaccine formulation: assessment of safety and protectiveness of influenza viral vectors expressing Brucella immunodominant proteins in mice and Guinea pigs
Sagi et al. Heterologous expression of Intimin and IpaB fusion protein in Lactococcus lactis and its mucosal delivery elicit protection against pathogenicity of Escherichia coli O157 and Shigella flexneri in a murine model
US20220023408A1 (en) Protective immunity enhanced salmonella vaccine (piesv) against brucella spp.
WO2007110462A1 (es) Vacuna contra la tuberculosis
ES2764173T3 (es) Bacterias modificadas para vacunas mejoradas contra la brucelosis
Stachyra et al. Highly immunogenic prime–boost DNA vaccination protects chickens against challenge with homologous and heterologous H5N1 virus
Shoemaker et al. Replicating vaccines
Arutkumaran et al. The role of vaccination in controlling swine zoonosis